Cincinnati Cohort Biomarkers Program
Posted Date: Mar 16, 2020
- Investigator: Alberto Espay
- Specialties: Memory Disorders, Movement Disorders, Neurology, Parkinson's Disease
- Type of Study: Observational/Survey
Viewing Parkinson's disease (PD), Alzheimer’s Disease (AD), and other neurodegenerative diseases as single entities has been useful in the identification of treatments for symptoms dependent on the degeneration of vulnerable neurons. The development of disease modifying therapies, on the other hand, will require a “precision medicine” approach, aiming at classifying those patients into distinctive molecular subtypes that are expected to respond to therapies differently (Espay et al., 2017; 2019). To respond to this need, we aim to assess the extent to which genetic and biological/molecular abnormalities may affect patterns of gait, balance, cognitive performance, neuroimaging, and at-home physical activities, as representing different clusters of the above-mentioned neurodegenerative conditions, namely PD-like/AD-like diseases, and suggesting distinct patterns of progression. Genetic and biological/molecular analyses will be performed to analyze their association with technology-based objective measures (TOMs), clinical data, and neuroimaging.
To Be Included, Patients Should Have Presence Of Documented Parkinsonian Features Such As Tremor, Rigidity, Bradykinesia, And Postural Instability; Or Diagnosis Of Pd, Essential Tremor, Normal Pressure Hydrocephalus, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, And Primary Progressive Freezing Of Gait; Or Diagnosis Of Dementia, Including Ad, Frontotemporal Dementia, Lewy Body Dementia, Dementia With Lewy Bodies, Mixed Dementia; Or Roll-Over Subjects From The Earlier Protocol, Study Of Biomarkers In Parkinson’S Disease And Related Disorders; And 18 Years And Above; And Willingness And Ability To Comply With Study Visits And Procedures.
Parkinson's, Alzheimers, Neurodegenerative Diseases
For More Information: